Can a simple blood test replace scans for pancreatic cancer patients?
NCT ID NCT07122466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test that measures tumor DNA (ctDNA) can predict how well chemotherapy is working in people with advanced pancreatic cancer. Researchers will compare the blood test results with CT scans taken before and two months after starting treatment. The goal is to see if the blood test is a reliable alternative to imaging, which could make monitoring easier for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simpler blood test to monitor treatment response in pancreatic cancer, reducing the need for frequent CT scans.
- What could go wrong
- This is a very small pilot study with only 24 participants, so results may not apply to everyone. It's observational, meaning it won't directly improve treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zuckerberg Cancer Center
New Hyde Park, New York, 11042, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Smart drug delivers chemo directly to pancreatic cancer cells
- Gene-Guided chemo cocktail aims to tame tough pancreatic cancer
- New blood test could spot hidden cancer cells that spread
- Could a stomach drug help fight pancreatic cancer?
- Could a diabetes drug boost chemo for tough cancers?